Besifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic. IC50 Value:Target: AntibacterialBesifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro. Besifloxacin is a novel 8-chloro-fluoroquinolone agent with potent, bactericidal activity against prevalent and drug-resistant pathogens.besifloxacin is the most potent agent tested against gram-positive pathogens and anaerobes and is generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrates potent, broad-spectrum activity, which is particularly notable against gram-positive and gram-negative isolates that are resistant to other fluoroquinolones and classes of antibacterial agents.
References:
[1]. Wang Z, Wang S, Zhu F, Chen Z, Yu L, Zeng S.Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high-performance liquid chromatography with precolumn derivatization.Chirality. 2012 Jul;24(7):526-31. doi: 10.1002/chir.22042.
[2]. Hussar DA.New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine.J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):570-4.
[3]. Nafziger AN, Bertino JS Jr.Besifloxacin ophthalmic suspension for bacterial conjunctivitis.Drugs Today (Barc). 2009 Aug;45(8):577-88.
[4]. Proksch JW, Ward KW.Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58.
[5]. Comstock TL, Paterno MR, Usner DW, Pichichero ME.Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.Paediatr Drugs. 2010 Apr 1;12(2):105-12. doi: 10.2165/11534380-000000000-00000.